Literature DB >> 10096590

Commercialization of BRCA1/2 testing: practitioner awareness and use of a new genetic test.

M K Cho1, P Sankar, P R Wolpe, L Godmilow.   

Abstract

It was our purpose to determine the characteristics of practitioners in the United States who were among the first to inquire about and use the BRCA1 and BRCA2 (BRCA1/2) genetic tests outside of a research protocol. Questionnaires were mailed to all practitioners who requested information on or ordered a BRCA1/2 test from the University of Pennsylvania (UPenn) Genetic Diagnostics Laboratory (GDL) between October 1, 1995 and January 1, 1997 (the first 15 months the test was available for clinical use). The response rate was 67% of practitioners; 54% (121/225) were genetic counselors, 39% (87/225) were physicians or lab directors. Most physicians were oncologists, pathologists, or obstetrician/gynecologists, but 20% practiced surgery or internal or general medicine. Fifty-six percent (125/225) had ordered a BRCA1/2 test for a patient; most of the rest had offered or were willing to offer testing. Of those who had offered testing, 70% had a patient decline BRCA1/2 testing when offered. Practitioners perceived that patients' fear of loss of confidentiality was a major reason for declining. Nearly 60% of practitioners reported that their patients had access to a genetic counselor, but 28% of physicians who ordered a BRCA1/2 test reported having no such access, despite the GDL's counseling requirement. The proportion of physicians reporting no access to genetic counselors for their patients increased from 22.4% in the first half of the study to 50% in the last half. Many practitioners have an interest in BRCA1/2 testing, despite policy statements that discourage its use outside of research protocols. Practitioner responses suggest that patient interest in testing seems to be tempered by knowledge of potential risks. An apparent increase in patient concern about confidentiality and inability to pay for testing could indicate growing barriers to testing. Although most practitioners reported having access to counseling facilities, perceived lack of such access among an increasing proportion of practitioners indicates that lab requirements for counseling are difficult to enforce and suggests that an increasing proportion of patients may not be getting access to counseling.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10096590      PMCID: PMC2225442          DOI: 10.1002/(sici)1096-8628(19990319)83:3<157::aid-ajmg4>3.0.co;2-g

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  35 in total

1.  Breaking ranks, lab offers test to assess risk of breast cancer.

Authors:  Gina Kolata
Journal:  N Y Times Web       Date:  1996-04-01

2.  Uptake of presymptomatic predictive testing for Huntington's disease.

Authors:  D Craufurd; A Dodge; L Kerzin-Storrar; R Harris
Journal:  Lancet       Date:  1989-09-09       Impact factor: 79.321

3.  Physicians' knowledge of genetics and genetic tests.

Authors:  K J Hofman; E S Tambor; G A Chase; G Geller; R R Faden; N A Holtzman
Journal:  Acad Med       Date:  1993-08       Impact factor: 6.893

4.  Uptake of cystic fibrosis testing in primary care: supply push or demand pull?

Authors:  H Bekker; M Modell; G Denniss; A Silver; C Mathew; M Bobrow; T Marteau
Journal:  BMJ       Date:  1993-06-12

5.  Scientific versus commercial sources of influence on the prescribing behavior of physicians.

Authors:  J Avorn; M Chen; R Hartley
Journal:  Am J Med       Date:  1982-07       Impact factor: 4.965

6.  Prevention in familial breast cancer: counseling and prophylactic mastectomy.

Authors:  J J Mulvihill; A W Safyer; J K Bening
Journal:  Prev Med       Date:  1982-09       Impact factor: 4.018

7.  On attitudes and appreciation 6 months after predictive DNA testing for Huntington disease in the Dutch program.

Authors:  A Tibben; P G Frets; J J van de Kamp; M F Niermeijer; M Vegtervan der Vlis; R A Roos; H G Rooymans; G J van Ommen; F Verhage
Journal:  Am J Med Genet       Date:  1993-07-15

8.  Ethical aspects of genetic disease and genetic counselling.

Authors:  R West
Journal:  J Med Ethics       Date:  1988-12       Impact factor: 2.903

9.  Predictive testing for Huntington disease: II. Demographic characteristics, life-style patterns, attitudes, and psychosocial assessments of the first fifty-one test candidates.

Authors:  M Bloch; M Fahy; S Fox; M R Hayden
Journal:  Am J Med Genet       Date:  1989-02

10.  Attitudes toward presymptomatic testing in Huntington disease.

Authors:  C Mastromauro; R H Myers; B Berkman
Journal:  Am J Med Genet       Date:  1987-02
View more
  13 in total

1.  Assessing the social meaning, value and implications of research in genomics.

Authors:  Blanca Lumbreras; Miquel Porta; Ildefonso Hernández-Aguado
Journal:  J Epidemiol Community Health       Date:  2007-09       Impact factor: 3.710

2.  Cancer risk assessment by rural and Appalachian family medicine physicians.

Authors:  Kimberly M Kelly; Margaret M Love; Kevin A Pearce; Kyle Porter; Mary A Barron; Michael Andrykowski
Journal:  J Rural Health       Date:  2009       Impact factor: 4.333

3.  Racial disparities in BRCA testing and cancer risk management across a population-based sample of young breast cancer survivors.

Authors:  Deborah Cragun; Anne Weidner; Courtney Lewis; Devon Bonner; Jongphil Kim; Susan T Vadaparampil; Tuya Pal
Journal:  Cancer       Date:  2017-02-09       Impact factor: 6.860

4.  Significant differences among physician specialties in management recommendations of BRCA1 mutation carriers.

Authors:  S U Dhar; H P Cooper; T Wang; B Parks; S A Staggs; S Hilsenbeck; S E Plon
Journal:  Breast Cancer Res Treat       Date:  2011-04-05       Impact factor: 4.872

Review 5.  Care delivery considerations for widespread and equitable implementation of inherited cancer predisposition testing.

Authors:  Deborah Cragun; Anita Y Kinney; Tuya Pal
Journal:  Expert Rev Mol Diagn       Date:  2016-12-13       Impact factor: 5.225

6.  How do women decide? Accepting or declining BRCA1/2 testing in a nationwide clinical sample in the United States.

Authors:  Pamela Sankar; Paul Root Wolpe; Nora L Jones; Mildred Cho
Journal:  Community Genet       Date:  2006

7.  The knowledge value-chain of genetic counseling for breast cancer: an empirical assessment of prediction and communication processes.

Authors:  Nabil Amara; Jolyane Blouin-Bougie; Jalila Jbilou; Norrin Halilem; Jacques Simard; Réjean Landry
Journal:  Fam Cancer       Date:  2016-01       Impact factor: 2.375

8.  Promotion of cancer family history awareness: Jameslink Cancer Risk Assessment Tool at community health fairs.

Authors:  Kimberly M Kelly; Kyle Porter; Amber Remy; Judith A Westman
Journal:  J Genet Couns       Date:  2008-05-17       Impact factor: 2.537

9.  Contralateral risk-reducing mastectomy in young breast cancer patients with and without genetic cancer risk assessment.

Authors:  Phuong L Mai; Veronica I Lagos; Melanie R Palomares; Jeffrey N Weitzel
Journal:  Ann Surg Oncol       Date:  2008-10-04       Impact factor: 5.344

10.  Cancer risk assessment using genetic panel testing: considerations for clinical application.

Authors:  Susan Hiraki; Erica S Rinella; Freya Schnabel; Ruth Oratz; Harry Ostrer
Journal:  J Genet Couns       Date:  2014-03-07       Impact factor: 2.537

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.